Skip to main content
SpringerLink
Log in

Challenges of Anticoagulation Therapy in Pregnancy

  • Pregnancy and Cardiovascular Disease (N Scott, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Thrombotic complications in pregnancy represent a major cause of morbidity and mortality. Pregnancy is a primary hypercoagulable state due to enhanced production of clotting factors, a decrease in protein S activity, and inhibition of fibrinolysis. These physiologic changes will yield a collective rate of venous thromboembolism (VTE) of about 1–2 in 1000 pregnancies for the general obstetric population, which represents a five- to tenfold increased risk in pregnancy compared to age-matched non-pregnant peers. A select group of women, however, will carry a significantly higher rate of thrombosis due to primary thrombophilia, either inherited or acquired. This introduces a population of women who may benefit from prophylactic anticoagulation, either antepartum or postpartum. The coagulation changes that occur in preparation for the hemostatic challenges of delivery endure for several weeks postpartum. In fact, daily risk for pulmonary embolism (PE) is the highest postpartum. Use of anticoagulation in pregnancy introduces particular risk at the time of delivery, where bleeding and clotting risk collide. Altered metabolism rates of anticoagulants in pregnant women often necessitate closer monitoring than is required outside of pregnancy in order to ensure efficacy and safety. Heparin products are the mainstay of treating VTE in pregnancy, chiefly because they do not cross the placenta. In women with mechanical heart valves, the ideal anticoagulation regimen remains controversial as heparin use has shown inferior outcomes for preventing thromboembolic complications compared to warfarin, but warfarin carries risk for fetal embryopathy. Other populations where a heparin alternative is necessary include women with a history of heparin-associated thrombocytopenia (HIT) or other heparin intolerance. Further challenging the management of anticoagulation in pregnancy is the dearth of randomized clinical trials. The evidence governing treatment recommendations is largely based on expert guidelines, observational studies, or extrapolation from non-pregnant cohorts. A careful critique of a woman’s history, as well as the available data, is essential for optimal management of anticoagulation in pregnancy. Such decisions should involve a multidisciplinary team involving obstetrics, hematology, cardiology, and anesthesia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. McDonnell BP, Glennon K, McTiernan A, O’Connor HD, Kirkham C, Kevane B, et al. Adjustment of therapeutic LMWH to achieve specific target anti-Xa acivity does not affect outcomes in pregnant patients with venous thromboembolism. J Thromb Thrombolysis. 2017;43(1):105–11.

  2. Petrie S, Barras M, Lust K, Fagermo N, Allen J, Martin JH. Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. Intern Med J. 2016;46(7):826–33.

    Article  CAS  PubMed  Google Scholar 

  3. Chow L, Carr A, MacKenzie L, Walker A, Archer D, Lee A. The effect of dalteparin on thromboelastography in pregnancy: an in vitro study. Int J Obstet Anesth. 2016;28:22–7.

    Article  CAS  PubMed  Google Scholar 

  4. Patil AS, Clapp T, Gaston PK, Kuhl D, Rinehart E, Meyer NL. Increased unfractionated heparin requirements with decreasing body mass index in pregnancy. Obstet Med. 2016;9(4):156–9.

  5. Patil AS, Clapp T, Gaston PK, Kuhl D, Rinehart E, Meyer NL. Increased unfractionated heparin requirements with decreasing body mass index in pregnancy. Obstet Med. 2016;9(4):156–9.

  6. Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol. 1990;97(3):221–8.

    Article  CAS  PubMed  Google Scholar 

  7. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168(4):1265–70.

    Article  CAS  PubMed  Google Scholar 

  8. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87(2):182–6.

    CAS  PubMed  Google Scholar 

  9. DeCarolis S, di Pasquo RE, Del Sordo G, Buonomo A, Schiavino D, Lanzone A, et al. Fondaparinux in pregnancy: could it be a safe option? A review of the literature. Thromb Res. 2015;135(6):1049–51.

  10. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants—and the challenge of event reporting. Thromb Haemost. 2016;116(4):651–8.

  11. Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105(2):117–26.

    Article  CAS  PubMed  Google Scholar 

  12. Leonhardt G, Gaul C, Nietsch HH, Buerke M, Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006;21(3):271–6.

    Article  PubMed  Google Scholar 

  13. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv. 1995;50(7):534–41.

    Article  CAS  PubMed  Google Scholar 

  14. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976;295:530–3.

    Article  CAS  PubMed  Google Scholar 

  15. Askie LM, Duley L, Henderson-smart DJ, Stewart LA, PARIS collaborative group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–8.

    Article  CAS  PubMed  Google Scholar 

  16. Duley, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;2:CD004659.

    Google Scholar 

  17. Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2009;1:CD004734.

    Google Scholar 

  18. Poutsie VJ, Dodd S, Drakeley AJ. Low-dose aspirin for in vitro fertilization. Cochrane Database Syst Rev. 2007;4:CD004832.

    Google Scholar 

  19. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 1994;343:619–29.

    Article  Google Scholar 

  20. Moore GS, Allshouse AA, Post AL, Galan HL, Heyborne KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU high-risk aspirin study. J Perinatol. 2015;35(5):328–31.

    Article  CAS  PubMed  Google Scholar 

  21. • Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV. Maternal and fetal outcomes of anticoagulation in pregnant women with mechanic heart valves. J Am Coll Cardiol. 2017;69(22):2681–91. The most recent meta-analysis again demonstrating that VKA use in women with mechanical heart valves is associated with fewer maternal complications, but LMWH throughout gestation is associated with the lowest risk for adverse fetal outcome.

    Article  PubMed  PubMed Central  Google Scholar 

  22. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, Sermer M, Shehata N. Anticoagulation for pregnant women with mechanical heart valves: a systemic review and meta-analysis. Eur Heart J. 2017.

  23. Xu Z, Fan J, Luo X, Zhang WB, Ma J, Lin YB, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systemic review and meta-analysis. Can J Cardiol. 2016;32(10):1248.e1–9.

  24. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systemic review and meta-analysis. Obstet Gynecol. 2010;115:1256–62.

    Article  PubMed  Google Scholar 

  25. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010;49:281–8.

    Article  CAS  PubMed  Google Scholar 

  26. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2. Suppl):e691S–736S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586–96.

  28. Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, et al., Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162–7.

  29. Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen, Bloemenkamp KW, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomized multicentre trial. Thromb Haemost. 2011;105(2):295–301.

  30. • Pasquier E, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood. 2015;125(14):2200–5. Another randomized trial showing no benefit of enoxaparin in preventing recurrent miscarriage.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. • Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, et al., ETHIG II group. Low-molecular-weight heparin for women with unexplained recurrent pregnant loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med. 2015;162(9):601–9. A large trial of 449 women demonstrating no benefit of dalteparin in preventing recurrent miscarriage.

  32. D’Souza R, Keating S, Walker M, Drewlo S, Kingdom J. Unfractionated heparin and placenta pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial. Placenta. 2014;35(10):816–23.

    Article  PubMed  Google Scholar 

  33. Haddad B, Heparin-Preeclampsia (HEPEPE) Trial Investigators, et al. Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial. Obstet Gynecol. 2016;128(5):1053–63.

    Article  CAS  PubMed  Google Scholar 

  34. Rodger MA, et al. TIPPS investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomized trial. Lancet. 2014;384(9955):1673–83.

    Article  CAS  PubMed  Google Scholar 

  35. De Jong PG, et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia—study protocol for a randomized controlled trial. Trials. 2015;16:208.

    Article  PubMed  PubMed Central  Google Scholar 

  36. • Stephenson ML, Serra AE, Neeper JM, Caballero DC, McNulty J. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. J Perinatol. 2016;36(2):95–9. A recent publication showing that obesity should be factored when determining the appropriate dose of thromboprophylaxis.

    Article  CAS  PubMed  Google Scholar 

  37. Boilot T, Raia-Barjat T, Ollier E, Chapelle C, Laporte S, Chauleur C. Influence of anticoagulant therapy during pregnancy on the peripartum and anesthesia delivery terms. Gynecol Obstet Fertil. 2015;43(7–8):502–8.

    Article  CAS  PubMed  Google Scholar 

  38. Wang EHZ, Marnoch CA, Khurana R, Sia W, Yuksel N. Haemorrhagic complications of peripartum anticoagulation: a retrospective chart review. Obstetric Med. 2014;7(2):77–83.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital, 55 Fruit Street, POB 224, Boston, MA, 02114, USA

    Annemarie E. Fogerty MD

Authors
  1. Annemarie E. Fogerty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annemarie E. Fogerty MD.

Ethics declarations

Conflict of Interest

Annemarie E. Fogerty declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pregnancy and Cardiovascular Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fogerty, A.E. Challenges of Anticoagulation Therapy in Pregnancy. Curr Treat Options Cardio Med 19, 76 (2017). https://doi.org/10.1007/s11936-017-0575-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-017-0575-x

Keywords

Search

Navigation